<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212403</url>
  </required_header>
  <id_info>
    <org_study_id>JessaH_B243201733480</org_study_id>
    <nct_id>NCT04212403</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)</brief_title>
  <acronym>Prophylaxis001</acronym>
  <official_title>A Prospective Study About the Safety of Omitting Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB): the prophylaxis001-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jessa Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the use of antibiotic prophylaxis in patients undergoing TURP and TURB. The
      investigators set up a prospective, randomized controlled trial in which (after exclusion of
      risk factors) patients will be randomized in receiving levofloxacin (Tavanic) orally or no
      antibiotics. The exclusion criteria for TURP are a pre-operative transurethral catheter or &gt;
      100 urinary white blood cells in the pre-operative urine sample. The exclusion criteria for
      TURB are a pre-op catheter or clinical signs of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:

      To investigate the safety of omitting antibiotic prophylaxis in TURP (transurethral resection
      of the prostate) and TURB (transurethral bladder tumour resection) in patients without a
      pre-operative catheter or &gt; 100 WBC in the pre-operative urinary sample (TURP) or clinical
      signs of urinary infection (TURB).

      Secondary objective:

      To investigate post-operative bacteriuria after TURB and TURP in our population.

      Principal inclusion criterium:

      Patients undergoing TURP or TURB.

      Primary exclusion criterium:

      TURP: pre-operative catheter or &gt; 100 white blood cells in the pre- operative urinary sample.

      TURB: pre-operative catheter or clinical signs of infection (fever, nyctalgia).

      Primary endpoint:

      Post-operative infection.

      Secondary endpoint:

      Post-operative bacteriuria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of patients with a post-operative infection.</measure>
    <time_frame>From immediately post-op until at the control consultation 4 weeks after surgery.</time_frame>
    <description>Urosepsis, fever (tÂ°&gt; 38.5) or epididymitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative bacteriuria.</measure>
    <time_frame>From immediately post-op until at the control consultation 4 weeks after surgery.</time_frame>
    <description>&gt; 100.000 bacteria/mL urine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1350</enrollment>
  <condition>Urosepsis</condition>
  <condition>Bladder Cancer</condition>
  <condition>Prostate Hyperplasia</condition>
  <condition>Antibiotic Resistant Strain</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <condition>Antibiotic-associated Diarrhea</condition>
  <condition>Antibiotic Toxicity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The treatment group receives no AMP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>The control group receives AMP.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TURP or TURB.

        Exclusion Criteria:

          -  TURP: pre-operative catheter/DJ/nephrostomy or &gt; 100 white blood cells in the pre-
             operative urinary sample.

        TURB: pre-operative catheter/DJ/nephrostomy or clinical signs of infection (fever,
        myctalgia).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koenraad van Renterghem, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHasselt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TURP</keyword>
  <keyword>TURB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

